Abstract:Antibodies are essential research tools whose performance directly impacts research conclusions and reproducibility. Owing to its central role in Alzheimer's disease and other dementias, hundreds of distinct antibody clones have been developed against the microtubule-associated protein Tau and its multiple proteoforms. Despite this breadth of offer, limited understanding of their performance and poor antibody selectivity have hindered research progress. Here, we validate a large panel of Tau antibodies by Western blot (79 reagents) and immunohistochemistry (35 reagents). We address the reagents' ability to detect the target proteoform, selectivity, the impact of protein phosphorylation on antibody binding and performance in human brain samples. While most antibodies detected Tau at high levels, many failed to detect it at lower, endogenous levels. By WB, non-selective binding to other proteins affected over half of the antibodies tested, with several cross-reacting with the related MAP2 protein, whereas the "oligomeric Tau" T22 antibody reacted with monomeric Tau by WB, thus calling into question its specificity to Tau oligomers. Despite the presumption that "total" Tau antibodies are agnostic to post-translational modifications, we found that phosphorylation partially inhibits binding for many such antibodies, including the popular Tau-5 clone. We further combine high-sensitivity reagents, mass-spectrometry proteomics and cDNA sequencing to demonstrate that presumptive Tau "knockout" human cells continue to express residual protein arising through exon skipping, providing evidence of previously unappreciated gene plasticity. Finally, probing of human brain samples with a large panel of antibodies revealed the presence of C-term-truncated versions of all main Tau brain isoforms in both control and tauopathy donors. Ultimately, we identify a validated panel of Tau antibodies that can be employed in Western blotting and/or immunohistochemistry to reliably detect even low levels of Tau expression with high selectivity. This work represents an extensive resource that will enable the re-interpretation of published data, improve reproducibility in Tau research, and overall accelerate scientific progress.

Identification and Characterization of DNA Aptamers Specific for Phosphorylation Epitopes of Tau Protein.

Functional Selection of Tau Oligomerization‐Inhibiting Aptamers

Enhanced Identification of Tau Acetylation and Phosphorylation with an Engineered Aerolysin Nanopore

Synthesis and conformational properties of phosphopeptides related to the human tau protein.

T232K/K238Q Aerolysin Nanopore for Mapping Adjacent Phosphorylation Sites of a Single Tau Peptide

Defined Tau Phosphospecies Differentially Inhibit Fast Axonal Transport Through Activation of Two Independent Signaling Pathways

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

Tau phosphosignatures discriminate Alzheimer Disease from other tauopathies

Enhanced in Vivo Blood-Brain Barrier Penetration by Circular Tau-Transferrin Receptor Bifunctional Aptamer for Tauopathy Therapy

Magnetic resonance investigation of conformational responses of tau protein to specific phosphorylation

O4‐12‐03: Brain Phosphoproteome Network Analysis Discriminates Alzheimer's Disease from Other Tauopathies

Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau

Pseudo-phosphorylation at AT8 Epitopes Regulates the Tau Truncation at Aspartate 421

Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry

Polyvalent Biotinylated Aptamer Scaffold for Rapid and Sensitive Detection of Tau Proteins

Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer's disease samples

Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer's disease

Single‐Molecule Characterization and Super‐Resolution Imaging of Alzheimer's Disease‐Relevant Tau Aggregates in Human Samples

Development of a pan‐tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates

Human genome‐wide analysis and identification of the hyperphosphorylation‐elicited interactions between subarachnoid tau protein and phosphoprotein‐binding domains